Syndax Pharmaceuticals Dirección

Dirección controles de criterios 1/4

El CEO de Syndax Pharmaceuticals' es Michael Metzger , nombrado en Feb 2022, tiene una permanencia de 2.17 años. compensación anual total es $9.13M, compuesta por 7.4% salario y 92.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.062% de las acciones de la empresa, por valor de €1.04M. La antigüedad media del equipo directivo y de la junta directiva es de 1.8 años y 7.8 años, respectivamente.

Información clave

Michael Metzger

Chief Executive Officer (CEO)

US$9.1m

Compensación total

Porcentaje del salario del CEO	7.4%
Permanencia del CEO	2.3yrs
Participación del CEO	0.06%
Permanencia media de la dirección	1.9yrs
Promedio de permanencia en la Junta Directiva	7.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Michael Metzger en comparación con los beneficios de Syndax Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$9m	US$678k	-US$209m
Sep 30 2023	n/a	n/a	-US$176m
Jun 30 2023	n/a	n/a	-US$160m
Mar 31 2023	n/a	n/a	-US$153m
Dec 31 2022	US$4m	US$640k	-US$149m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	US$818k
Mar 31 2022	n/a	n/a	US$15m
Dec 31 2021	US$3m	US$594k	US$25m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$91m
Mar 31 2021	n/a	n/a	-US$86m
Dec 31 2020	US$2m	US$577k	-US$77m
Sep 30 2020	n/a	n/a	-US$71m
Jun 30 2020	n/a	n/a	-US$63m
Mar 31 2020	n/a	n/a	-US$61m
Dec 31 2019	US$3m	US$540k	-US$56m
Sep 30 2019	n/a	n/a	-US$61m
Jun 30 2019	n/a	n/a	-US$65m
Mar 31 2019	n/a	n/a	-US$69m
Dec 31 2018	US$2m	US$506k	-US$74m
Sep 30 2018	n/a	n/a	-US$74m
Jun 30 2018	n/a	n/a	-US$72m
Mar 31 2018	n/a	n/a	-US$67m
Dec 31 2017	US$1m	US$492k	-US$61m

Compensación vs. Mercado: La compensación total de Michael($USD9.13M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.63M).

Compensación vs. Ingresos: La compensación de Michael ha aumentado mientras la empresa no es rentable.

CEO

Michael Metzger (52 yo)

2.3yrs

Permanencia

US$9,127,419

Compensación

Mr. Michael A. Metzger, M.B.A. serves as Chief Executive Officer at Syndax Pharmaceuticals, Inc since February 03, 2022 and has been its Director since July 4, 2019. He served as Senior Vice President and...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael Metzger	CEO & Director	2.3yrs	US$9.13m	0.062% $ 1.1m
Neil Gallagher	President	1.1yrs	US$4.04m	0.015% $ 274.5k
Keith Goldan	CFO, Treasurer & Chief Accounting Officer	1.9yrs	US$2.83m	0.017% $ 309.0k
Luke Albrecht	Senior VP	7.8yrs	US$2.59m	0.051% $ 905.0k
Catherine Madigan	Chief Medical Officer	2.2yrs	US$2.81m	0.043% $ 755.8k
Peter Ordentlich	Co-Founder & Chief Scientific Officer	18.6yrs	sin datos	0.00031% $ 5.5k
Richard Heyman	Co-Founder	no data	sin datos	sin datos
Ronald Evans	Co-Founder	no data	sin datos	sin datos
Michael Downes	Co-Founder	no data	sin datos	sin datos
Sharon Klahre	Vice President of Investor Relations & Communications	1.9yrs	sin datos	sin datos
Kevin McManus	Chief People Officer	less than a year	sin datos	sin datos
Joseph Eder	Member of Scientific Advisory Board & Chief Medical Officer	1.4yrs	sin datos	sin datos

1.9yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 1T3 no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael Metzger	CEO & Director	4.8yrs	US$9.13m	0.062% $ 1.1m
Ronald Evans	Co-Founder	7.8yrs	sin datos	sin datos
Joseph Eder	Member of Scientific Advisory Board & Chief Medical Officer	7.8yrs	sin datos	sin datos
Keith Katkin	Independent Director	7.2yrs	US$581.02k	0.038% $ 669.5k
Pierre Legault	Independent Director	7.3yrs	US$575.59k	0.038% $ 669.5k
Dennis Podlesak	Independent Chairman	15.4yrs	US$1.10m	0.017% $ 301.8k
George Sledge	Member of Scientific Advisory Board	7.1yrs	US$23.05k	sin datos
Jedd D. Wolchok	Member of Scientific Advisory Board	7.8yrs	sin datos	sin datos
Briggs W. Morrison	Director	8.8yrs	US$30.91k	0.021% $ 373.1k
Hope Rugo	Member of Scientific Advisory Board	7.8yrs	sin datos	sin datos
Samir Khleif	Member of Scientific Advisory Board	7.8yrs	sin datos	sin datos
Julie Brahmer	Member of Scientific Advisory Board	8.4yrs	sin datos	sin datos

7.8yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de 1T3 se considera experimentada (7.8 años de antigüedad promedio).

Syndax Pharmaceuticals Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 15, 2024

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

Insufficient new directors

Insufficient new directors

Recent updates

Syndax Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 15, 2024

Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

Syndax Pharmaceuticals, Inc. Announces Executive Changes

New minor risk - Profitability

Syndax Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Now 24% undervalued

Syndax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999985 million.

Syndax Pharmaceuticals Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Syndax Pharmaceuticals Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting

Syndax Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Syndax Pharmaceuticals Announces to Initiate Nda Submission of Revumenib in Relapsed/Refractory Kmt2ar Acute Leukemia Under Fda's Real-Time Oncology Review Program

New minor risk - Share price stability

Syndax Pharmaceuticals Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stated Interim Analysis

Syndax Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

Insufficient new directors

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.40 loss in 3Q 2021)

Syndax Pharmaceuticals, Inc. Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of Augment-101 Trial of Revumenib in Patients with Acute Leukemias

Syndax Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

First half 2022 earnings released

Syndax Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Insufficient new directors

Investor sentiment improved over the past week

Syndax Pharmaceuticals, Inc. Announces Appointment of Keith A. Goldan as Chief Financial Officer

Investor sentiment improved over the past week

First quarter 2022 earnings released: US$0.63 loss per share (vs US$0.54 loss in 1Q 2021)

Syndax Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 09, 2022

Investor sentiment improved over the past week

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals, Inc. Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613

Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease

Third quarter 2021 earnings released: US$0.40 loss per share (vs US$0.46 loss in 3Q 2020)

Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million.

First half 2021 earnings released: US$0.98 loss per share (vs US$0.97 loss in 1H 2020)

First quarter 2021 earnings released: US$0.54 loss per share (vs US$0.56 loss in 1Q 2020)

Independent Chairman recently bought €164k worth of stock

Full year 2020 earnings released: US$1.87 loss per share (vs US$1.84 loss in FY 2019)

Revenue beats expectations

Syndax Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 08, 2021

Syndax Pharmaceuticals, Inc. Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD

New 90-day high: €19.50

Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting

New 90-day high: €16.00

Third quarter 2020 earnings released: US$0.46 loss per share

Revenue misses expectations

Syndax Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 02, 2020

New 90-day high: €15.30

New 90-day high: €14.50

First half earnings released

Syndax Pharmaceuticals, Inc. announced that it has received funding from Frazier Healthcare Partners

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media